Vitamin B6 (Pyridoxine)
Of 15,354 on-market vitamin b6 (pyridoxine) products in the January 2026 DSLD dump, the median declared dose is 5 mg, and 89.5% list Pyridoxine Hydrochloride as the primary form.
Form share
Of 14,501 products with an identifiable primary form, here is the share held by each form of Vitamin B6 (Pyridoxine) on the market today.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Pyridoxine Hydrochloride | Unrated | 12,983 | 89.5% |
| Pyridoxal-5-Phosphate (P5P) | Unrated | 1,518 | 10.5% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 14,257 products with a disclosed amount, against the RDA of 1.3 and UL of 100.
- 0.6% of products don't disclose an amount because Vitamin B6 (Pyridoxine) is declared inside a proprietary blend.
By dosage form
By target group
Top brands
| Brand | Products |
|---|---|
| Douglas Laboratories | 324 |
| DC | 246 |
| Centrum | 186 |
| Wonder Laboratories | 184 |
| Cellucor | 175 |
| Source Naturals | 158 |
| Nature's Way | 152 |
| Country Life | 143 |
| Nature Made | 124 |
| Emergen-C | 122 |
| Metagenics | 121 |
| Pure Encapsulations | 120 |
| NOW | 117 |
| The Vitamin Shoppe | 115 |
| MegaFood | 112 |
| Higher Nature | 109 |
| Solgar | 101 |
| Bluebonnet | 98 |
| Life Extension | 97 |
| XYMOGEN | 94 |
| New Chapter | 94 |
| Puritan's Pride | 91 |
| Bayer One A Day | 88 |
| Vitamin World | 85 |
| GNC Mega Men | 81 |
Forms explained
Elemental fraction: 82.3% (pyridoxine free base MW 169.18 / pyridoxine HCl MW 205.64 (confirmed PubChem formula))
Requires oxidation/phosphorylation in the liver to become the active coenzyme PLP -- a plausible basis for tier differentiation, but no verifiable head-to-head human bioavailability RCT vs P5P was located; the widely-repeated "P5P is more bioavailable" marketing claim is not confirmed.
Source: uncertain -- needs review (no primary source found for this specific comparison)
The biochemical logic (already the active coenzyme, bypassing conversion) is sound in principle, but no confirmed comparative human trial supports a specific tier ranking over pyridoxine HCl -- do not assert P5P superiority without a real study.
Source: uncertain -- needs review
Reference values
- RDA (adult): 1.3 mg — 1.3mg (ages 19-50, both sexes); 1.7mg (men 51+); 1.5mg (women 51+)
- Tolerable Upper Intake Level (adult): 100 mg — Based on sensory neuropathy as the critical adverse effect
- Studied clinical dose range: ?–? mg
- Deliberately left null -- no verified low- or high-dose BENEFIT-efficacy RCT was confidently identified. The one directly relevant, verifiable study found is a toxicity/dose-response study underlying the UL, not a benefit-dose trial: Berger AR et al. 1992, Neurology 42(7):1367-1370, PMID 1620347 -- established the dose-response relationship between chronic high-dose pyridoxine and sensory neuropathy.
- Note: Weakest-evidenced compound in this file: the widely-repeated marketing claim that pyridoxal-5-phosphate (P5P) is meaningfully more bioavailable than pyridoxine HCl could not be traced to any verifiable primary human RCT -- treat both forms' quality_tier as null/uncertain in forms.yaml rather than asserting P5P superiority.